Toggle SGML Header (+)

Section 1: 8-K (8-K)






Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):    October 3, 2018

Commission File Number: 0-24260





Amedisys, Inc.

(Exact name of registrant as specified in charter)




Delaware   11-3131700

(State or other jurisdiction

of incorporation or organization)


(IRS Employer

Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐






Item 7.01.

Regulation FD Disclosure.

On October 3, 2018, Amedisys, Inc. (the “Company”) issued a press release announcing that it had entered into an Amended and Restated Employment Agreement with Paul B. Kusserow, the Company’s President and Chief Executive Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.



Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.





99.1    Press Release dated October 3, 2018


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


By:   /s/ Paul B. Kusserow
Paul B. Kusserow
President and Chief Executive Officer
DATE: October 3, 2018
(Back To Top)

Section 2: EX-99.1 (EX-99.1)


Exhibit 99.1





Kendra Kimmons

Vice President of Marketing & Communications


[email protected]

Amedisys Extends Employment Agreement with CEO Paul Kusserow

On Heels of Company Turnaround, Will Stay On For Three More Years

BATON ROUGE, La., October 3, 2018 — Amedisys, Inc. (NASDAQ:AMED), America’s leading independent home health, hospice and personal care company, announced today that it has extended its employment agreement with Paul Kusserow, its president and CEO, from September 27, 2018 to December 16, 2021, adding three more years.

Kusserow joined the Company on December 11, 2014. In the nearly four years since then, he has led Amedisys in a dramatic turnaround clinically, culturally and financially. Under Kusserow’s leadership, Amedisys’ home health star ratings reached an industry-leading average of 4.38 stars; its stock has nearly quintupled, from $26 to an all-time high of $124 and its market cap has almost quadrupled, from $889 million to $3.84 billion.

“I’m excited to have the opportunity to continue the job we started less than four years ago,” Kusserow said. “Yet in many respects, I feel as if we’re only now getting going. Every organization needs a sense of stability and continuity to keep growing and striving for excellence. I look forward to working with this outstanding executive leadership team and our more than 19,000 employees to realize our strategy of becoming the solution for those who want to age in place. I consider it an honor and privilege to continue caring for seniors where they most want to be—in the home.”

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 59,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With 18,300 employees in 420 care centers in 34 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 369,000 patients and clients in need every year. For more information about the Company, please visit:

#     #     #

(Back To Top)